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ABSTRACT
Delayed immunologic recovery after allogeneic bone marrow transplantation (BMT) represents a major cause
of morbidity and mortality that limits the overall success of the transplantation procedure. Recent clinical data
suggest that a subset of donor dendritic cells may inhibit the graft-versus-tumor activity of donor T cells. We
studied the immunoregulatory activity of donor dendritic cells in allogeneic BMT between major histocom-
patibility complex–disparate strains of mice. Bone marrow grafts enriched or depleted of CD11b and CD11b
dendritic cell subsets by immunomagnetic cell sorting were combined with small numbers of congenic splenic
T cells. Recipients of CD11b-depleted bone marrow had significant posttransplantation expansion of donor
spleen–derived CD4 memory T cells compared with recipients of unmanipulated bone marrow. CD11b
depletion enhanced the antitumor activity of the splenic donor T cells without producing significant graft-
versus-host disease and resulted in long-term survival after a supralethal dose of T-cell leukemia administered
after BMT. Expansion of donor spleen–derived T cells was proportional to the number of CD11b dendritic
cells in the bone marrow graft and was associated with increased levels of serum interferon-. Thus, manip-
ulating the content of donor antigen-presenting cells in allogeneic BMT is a novel strategy to activate donor
memory T cells and enhance allogeneic graft-versus-leukemia effects with minimal graft-versus-host disease.
© 2004 American Society for Blood and Marrow Transplantation
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tNTRODUCTION
Immune responses after allogeneic transplantation
re regulated by the interaction of donor T cells with
ntigen presented by dendritic cells and other anti-
en-presenting cells (APCs) [1-4]. Recent data have
ndicated that both recipient and donor APCs are
mportant in regulating immune responses after allo-
eneic bone marrow transplantation (BMT) [1-5].
he presence of host-type dendritic cells (DCs) is
trongly associated with the development of graft-
ersus-host disease (GVHD) in BMT patients with
alignancies [5] and is necessary for the initiation of
D8 T cell–mediated GVHD in a murine model of
inor and major histocompatibility complex (MHC)–40ismatched congenic BMT [2]. Larger numbers of
ymphoid CD123 DC precursors in the bone mar-
ow (BM) allograft are associated with decreased
hronic GVHD and increased relapse among patients
ith hematologic malignancies who receive non–T
ell–depleted BM from HLA-matched siblings [1].
he content of donor-derived DC precursors in the
lood at the time of hematopoietic engraftment is
ssociated with the incidence of relapse, GVHD, and
verall posttransplantation survival [6]. These clinical
ata suggest a relationship between donor DC sub-
ypes and their capacity to regulate the activation of
lloreactive T cells in response to indirect presenta-
ion of alloantigen.Currently, a model in which different DC subsets
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Immunoregulation by Donor APCs in BMT
Birect naive T cells toward either T-helper (Th)1 or
h2 differentiation has been developed on the basis of
n vitro experiments using phenotypically deﬁned hu-
an DC subsets incubated with antigen [7,8]. My-
loid human DCs direct naive T cells toward Th1
olarization [9], whereas lymphoplasmacytoid DCs
irect naive T cells toward Th2 polarization [10,11].
owever, the role of different DC subsets in immune
esponses after allogeneic BMT remains undeﬁned
12,13]. A murine model to explore the relationship
etween different donor DC subsets and transplanta-
ion outcomes would be useful to engineer the cellular
onstituents of the allogeneic graft and enhance the
raft-versus-leukemia (GVL) effect with limited
VHD.
The 5 phenotypically distinct subsets of murine
D11c DCs and DC precursors can be divided into
groups: 1 group that lacks CD11b expression
CD11bCD8DEC-205, CD11bCD4CD8low-
EC-205, and CD11bCD4CD8DEC-205
ubsets) and a second group that expresses CD11b
CD11bCD4CD8DEC-205 and CD11bCD4-
D8DEC-205) [14]. Both CD11b/CD8
lymphoid) and CD11b/CD8 (myeloid) murine
Cs efﬁciently stimulate T-cell responses to protein-
ntigen or alloantigen in vitro and in vivo [15,16]. The
urine equivalent of the human preplasmacytoid DC
CD11cB220CD45RACD11bCD4CD8 and
HC class II) [17] produces large amounts of inter-
eron (IFN)–alfa in response to oligodeoxynucleotides
ontaining cytosine phosphorate guanine (CPG) and
iral infection [18]. In contrast to the human plasma-
ytoid DCs, the murine plasmacytoid DC equivalents
ake large amounts of interleukin (IL)–12 in response
o activation signals of Staphylococcus aureus strain
owan I bacteria (SAC), CPG, and lipopolysaccharide
lus CD40L [19]. Furthermore, CD11b and CD8
redominantly synthesize IL-12 p70 and trigger Th1
esponses, whereas CD11b and CD8 DCs polar-
ze T cells toward Th2 or mixed Th1/Th2 responses
7,8]. Thus, the relationship between phenotypically
eﬁned murine DC subsets, the corresponding human
unctional DC equivalents, and Th1 versus Th2 po-
arization of responding T cells is not clearly deﬁned.
We hypothesized that posttransplantation immu-
ity may be regulated, in part, by the relative numbers
f DCs and DC precursor subsets in the BM graft.
D11b is a convenient antigenic marker with which
o remove 1 subset of DCs and DC progenitors with-
ut substantially affecting the content of T cells or
tem cells. We measured the posttransplantation ex-
ansion of allogeneic donor T cells that were marked
n their surface with a congenic antigen and co-trans-
lanted with allogeneic BM cells enriched or depleted
f CD11b cells. The GVL activity of engrafted do-
or T cells was assessed to test the hypothesis that
ltering the content of donor APCs in the BM graft C
B&MTould enhance functional immunity after allogeneic
MT. The data conﬁrm the prediction that removal
f donor CD11b BM cells (simultaneously decreas-
ng the content of putative immunoregulatory
D11b DCs and increasing the content of CD11b
Cs) would signiﬁcantly enhance posttransplantation
ellular immune reconstitution and GVL activity of
onor T cells without causing signiﬁcant GVHD in
llogeneic BMT.
ATERIALS AND METHODS
ice
B10.BR (H-2k) and C57BL/6SJL (H-2b) congenic
trains (CD90.2/CD45.1 and CD45.2/CD90.2)
f C57BL/6 were purchased from Jackson Laborato-
ies (Bar Harbor, ME). Congenic strains (expressing
D90.1 and CD45.1 on a C57BL/6 background and
xpressing CD90.1 and CD45.2 on a B10.BR back-
round) were bred at the Emory University Animal
are Facility.
BRM Tumor Cell Line
The mouse LBRM 33 5A4 T lymphoma cell line
20] was purchased from the American Type Culture
ollection (Manassas, VA), passaged according to
merican Type Culture Collection recommendations,
nd tested to be free of lymphocytic choriomeningitis
irus, mouse hepatitis virus, MMV, and MPV by the
niversity of Missouri Research Animal Diagnostic
aboratory.
onor Cell Preparation
Femurs and tibiae were washed in 70% ethanol for
minutes, followed by 5 washes with phosphate-buff-
red saline. BM cells were ﬂushed out with a 25-gauge
eedle in RPMI 1640 medium containing 1% heat-
nactivated fetal calf serum. Splenocytes were har-
ested by perfusing the spleen with sterile RPMI and
etal calf serum.
M CD11b Depletion and Splenic T-Cell
urification
BM cells and splenocytes were incubated with
nti-FcR 16/32 antibody (Pharmingen, San Diego,
A), biotinylated anti-CD11b antibody, 10 L of
treptavidin microbeads (Miltenyi Biotech GmbH,
ergisch Gladbach, Germany), and 90 L of labeling
uffer (phosphate-buffered saline containing 2
mol/L ethylenediaminetetraacetic acid and 0.5% bi-
tin-free bovine serum albumin) per 107 cells. A Vario
ACS column C (Miltenyi Biotech) separated
D11b and CD11b cell fractions with 99.9% de-
letion and 87%  3% purity, respectively. Partially
D11b-depleted BM was a 50:50 mix of unmanipu-
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5ated and CD11b-depleted BM. Splenic T cells were
uriﬁed by incubating with biotinylated anti-CD11b,
220, DX5, and TER119 antibodies and 10 L of
treptavidin microbeads per 107 cells by using an LS
ario MACS column and collecting unbound cells
ith a CD3 cell purity of 93%  2%.
ransplant Conditioning Regimen
Two days before BMT, recipient mice were irra-
iated with 11 Gy in 2 equal fractions 3 hours apart at
.24 Gy/min [21-22]. Irradiated mice were maintained
n oral aqueous antibiotics (neomycin sulfate 1.1
g/mL and polymyxin sulfate 1000 U/mL) for 4
eeks after BMT.
M Transplantation and Leukemia Challenge
Combinations of BM, splenocytes, or puriﬁed T
ells were administered in a single tail vein injection
n day 0. Recipient mice were challenged with 10
imes the lethal dose of LBRM tumor cells (3  106)
n day 75 after transplantation.
low Cytometry of BM and Spleen
DC subsets in BM and splenocytes were assessed
y staining with anti-CD11c/ﬂuorescein isothiocya-
ate (FITC); anti–B220-, anti–CD8-, or anti–CD4-
yChrome; anti-CD11b or anti-B220 APCs; and a
ocktail of phycoerythrin (PE)-conjugated antibodies
o lineage-associated antigens (Lin; anti-CD3, anti-
D5, anti-CD19, anti-DX5, anti–surface immuno-
lobulin M, and anti-TER119) [18]. DC maturation
tatus was deﬁned by MHC class II (I-Ab) expression
23-25]. Multipotent hematopoietic progenitor cells
HPC) lacked expression of Lin markers (B220, CD3,
D4, CD8, CD11b, CD11c, DX5, Gr-1, TER119,
nd I-Ab) and coexpressed sca-1 and c-kit [26]. T-cell
ubsets were stained with anti-CD45 FITC, anti-CD4
E, anti-CD8 peridinin chlorophyll (PerCP), and an-
i-CD3 APC.
nalyses of Hematopoietic Engraftment
Viable leukocytes in peripheral blood were
ounted in a hemacytometer after staining with
thidium bromide/acridine orange. Blood leukocytes
ere depleted of red blood cells by ammonium chlo-
ide lysis and washed twice, and 50000 to 100000 list
ode events were collected on a FACS Calibur (Bec-
on Dickinson, San Jose, CA). FACS ﬁles were ana-
yzed with Cell Quest software (Becton Dickinson,
an Jose, CA). Host and donor leukocytes were enu-
erated by using monoclonal antibodies speciﬁc for
-2b and H-2k MHC, and congenic markers
CD45.2, CD45.1, CD90.1, and CD90.2; Pharmin-
en) were used with CD62L FITC and CD44 PE to
numerate naive and memory T-cell subsets, respec-
ively. C
42erum IFN- and Tumor Necrosis Factor-
nzyme-Linked Immunosorbent Assay
Serum samples were collected from mouse tail
ein blood by using Microtainer serum-separator
ubes (Becton Dickinson, Franklin Lakes, NJ) and
ere analyzed for IFN- and tumor necrosis factor
TNF)- by using OptEIA enzyme-linked immu-
osorbent assay kits (Pharmingen). They were then
nalyzed with a SpectraMax 340PC spectrophotome-
er (Molecular Devices, Sunnyvale, CA).
ssessments of Survival and GVHD in Transplant
ecipients
Clinical signs of GVHD (weight loss, posture,
ctivity, fur texture, and skin integrity) were graded
eekly from 0 to 2 for each criterion [27]. Moribund
ice, animals that lost 25% of their body weight,
nd mice that survived to the end of the experiment
ere killed. Samples of liver and gastrointestinal tract
ere ﬁxed in 10% formalin and embedded in parafﬁn.
istology sections (5 m) were stained with hematox-
lin and eosin and scored for GVHD [21,28-30].
tatistical Analyses
Survival differences among groups were calculated
ith the Kaplan-Meier log-rank test in a pairwise
ashion [21]. Differences in GVHD scores among
roups were compared by using the Mann-WhitneyU
est [27]. Differences of chimerism, levels of donor T
ells, and cytokine levels among groups were com-
ared by using the 1-way analysis of variance.
ESULTS
D11b DCs in BM Are Predominately Immature
nd Express Myeloid Markers
Because CD11b is not a marker restricted to DCs
31,32], we ﬁrst determined the pattern of CD11b ex-
ressed on DC subsets, hematopoietic progenitors, and
cells in BM cell suspensions. DCs were phenotypically
eﬁned as those cells with the forward and side scatter
roperties of large lymphocytes and monocytes (Figure
A); that lacked markers for T cells, natural killer (NK)
ells, B cells, and erythrocytes (Lin); and that expressed
ow, intermediate, or high levels of CD11c (Figure 1B).
he population of LinCD11clow-hi cells was phenotyp-
cally heterogeneous and could be subdivided on the
asis of expression patterns of MHC class II (I-Ab),
D11b, and CD4 (Figure 1C and D). LinCD11clow-hi
M (CD11b and CD11b) contained few I-Ab cells,
marker for more mature DCs (Figure 1C) [24]. The
inCD11clow-hiCD11b BM cells were nearly all
D4 (lower right quadrant, Figure 1D) and lacked
D8 expression (data not shown), whereas most of the
D11b DC subsets expressed B220 (data not shown).
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Immunoregulation by Donor APCs in BMT
Bn contrast, analyses of splenic DC subsets by using
imilar ﬂow cytometric gating strategies showed that
-Ab (mature) cells predominated in the CD11b sub-
et (Figure 1E), and a substantial population of DCs
oexpressing CD11b and CD4 was seen (Figure 1F).
igure 1. Phenotypes of DCs and DC precursor subsets in freshly
solated BM cells and splenocytes. Cells from BM (A-D) and spleen (E
nd F) of C57BL/6 mice were stained with CD11c, B220, CD11b,
D4, CD8, and a lineage (Lin) cocktail consisting of anti-CD3, CD5,
D19, DX5, surface immunoglobulin M, and TER-119 monoclonal
ntibodies. A, Electronic gates were placed by using forward and side
catter properties of large lymphocytes and monocytes in BM. B,
lectronic gates were placed around the subpopulation of cells deﬁned
n panel A limited to those cells lacking lineage marker expression and
xpressing low to high levels of CD11c. C and E, The population of
ells included in the gates deﬁned in panels A and B was further
ubdivided on the basis of expression patterns of MHC class II (I-Ab)
nd CD11b. D and F, The population of cells included in the gates
eﬁned in panels A and B was subdivided on the basis of expression
atterns of CD11b and CD4.
able 1. The Content of Cell Subsets in CD11b-Manipulated BM and
Total No.
Cells in the
BM or
Spleen Cell
Graft Graft Constituent
CD3
(103)
 106 cells
CD11b [] BM 80  30
Unmanipulated BM 66  10
CD11b [/] BM 95  25
CD11b [] BM 135  30†
 106 cells Unmanipulated Spleen 237  14
ata represent the number of HPCs (LineageSca-1c-kit), T ce
subsets among the overall hematopoietic (nucleated) cells of the
(BM), CD11b enriched (CD11b[]), partially CD11b depleted (
for each group are shown (n 
 5 separate samples of BM and s
between CD11b-depleted or CD11b-enriched BM and unmanipulated
B&MTD11b Depletion Did Not Change the Overall
umber of DCs, Stem Cells, or T Cells in the
raft
We have previously described the ability of low-
ose splenocytes (1  106 cells) to mediate GVL
ctivity in the C57BL/63B10.BR transplant model
21,22], and we used this model to explore the effect of
onor DCs on posttransplantation immunity, taking
dvantage of congenic strains in which the fate of
onor BM–derived and donor spleen–derived T cells
an be observed by using antibodies to the Thy 1.1
nd Thy 1.2 markers expressed on mature T cells [21].
ransplantation across this major MHC disparity (H-
b3H-2k) requires a relatively large number (5 
06) of donor BM cells [21] to ensure engraftment in
he absence of added donor T cells and requires donor
pleen cell doses of 1  106 to avoid lethal GVHD
21,22]. Therefore, we characterized the number of
Cs, T cells, NK cells, and HPCs in an engrafting
ose of BM (5  106 cells) and a nonlethal dose of
plenocytes (1 106). Five million BM cells contained
8  103 CD11b DCs and 37  103 CD11b DCs,
hereas 1 million splenocytes contained 20  103
D11b DCs and 6  103 CD11b DCs (Table 1).
our different BM grafts were studied: BM cells that
ere unmanipulated, CD11b depleted (CD11b []
M), partially CD11b depleted (CD11b [/] BM,
epresenting a 50:50 combination of unmanipulated
M and CD11b-depleted BM), or CD11b enriched
CD11b [] BM). Calculating the net number of DCs
n the combination of 1  106 splenocytes with 5 
06 BM cells, we determined that depletion of
D11b cells from the BM graft led to a small in-
rease in the content of total DC/DC precursors, with
2  6  103 total DCs in the combination of unma-
ipulated BM plus splenocytes, 106  6  103 total
Cs with CD11b [/] BM and splenocytes, and
21  8  103 total DCs with CD11b [] BM plus
plenocytes (P 	 .05). CD11b depletion resulted in
yte Graft Constituents
bers of Cellular Subsets in the Graft Constituent
NK
103)
HPC
(103)
CD11b DC
and pDC
(103)
CD11b DC
and pDC
(103)
 6 4.5  1.5 47  6* 23  3†
 3 4.5  1.5 28  5 37  8
 7 3.5  1.5 14  3‡ 66  6*
 14 3  1 0.3  0.08‡ 94  10‡
 2.0 0.2  0. 20  1.8 6.4  1
3). NK cells (NK 1.1CD3), and CD11b or CD11b DC cell
BM and 1  106 splenocyte grafts. BM grafts were unmanipulated
[/]), or fully CD11b depleted (CD11b[]). Mean value and SD
Signiﬁcant differences (*P 	 .01; †P 	 .05; ‡P 	 .001) are shownSplenoc
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5elative enrichment of the CD11b DC population
1.89% versus 0.75% in unmanipulated BM), with no
igniﬁcant effect on the number of phenotypically
eﬁned multipotent HPCs (stem cells) or NK cells in
he combined graft (Table 1) and a small increase in
he frequency of BM CD3 T cells (Table 1). How-
ver, because more than 75% of the T cells in the
ombined graft were contributed by the spleen cell
omponent, manipulation of the BM graft did not
esult in a signiﬁcant difference in the total number of
onor T cells between the various combinations of
M and splenocytes (P  .05).
ransplanting CD11b-Depleted BM Grafts Alone
r in Combination with Low-Dose Splenocytes
id Not Adversely Affect Survival Among
ecipients of Allogeneic BMT
Transplanting CD11b-depleted BM grafts alone
esulted in uniformly high posttransplantation survival
ithout evidence of GVHD (Table 2). The degree of
onor chimerism among recipients of different donor
M grafts at day 30, day 60, and day 105 was 99.1%
.3%, 99.8%  0.4%, and 99.9%  0.3%, respec-
ively, and there was no signiﬁcant difference in chi-
erism among the recipients of the different types of
M grafts (data not shown). Transplantation of
D11b-depleted BM grafts with low-dose splenocytes
0.5  106 or 1  106) resulted in a slight increase of
onlethal GVHD, as evidence by transient weight
oss, but no signiﬁcant histologic evidence of GVHD
Figure 2; Table 3). B10.BR mice that underwent
ransplantation with higher doses of splenocytes (5 
06 or 10  106) in combination with 5  106 BM
ells all developed fatal GVHD, except when the BM
raft was CD11b [] BM (Table 2).
able 2. Graded Doses of C57BL/6 Allogeneic Splenocytes Resulted in
quivalent GVHD in B10.BR Recipients Transplanted with
ombinations of Unmanipulated or CD11b-Depleted C57BL/6 BM
BM graft (5  106)
SP dose (106)
0 0.5 1.0 5.0 10.0
D11b [] BM 100 100 100 100 ND
nmanipulated BM 100 100 95 (80) 20 (35)* 0 (21)*
D11b [/] BM 100 100 90 (52) 20 (48)* 0 (36)*
D11b [] BM 100 100 90 (51) 10 (42)* 0 (31)*
verall survival at 100 days was determined for groups of B10.BR
mice transplanted with combinations of 5  106 BM and various
numbers of splenocytes from C57BL/6 donors. Data for each
group were pooled from 2 or 3 experiments. Each group had at
least 10 mice per group, except groups that received BM alone
or the combination of BM and 10  106 splenocytes, which had
5 mice per group. The numbers in parentheses are the median
day of death.
D indicates not done; SP, splenocytes.
ata are survival (%).
P 	 .001 versus survival with the same type of BM graft withoutCadded splenocytes.
44ecipients of CD11b-Depleted BMT Had More
pleen-Derived Donor T Cells in the Blood after
ransplantation
Peripheral blood samples from recipients of the
ombination of 1  106 donor splenocytes with unma-
ipulated BM, CD11b [/] BM, CD11b [] BM, or
D11b [] BM were analyzed for the presence of cir-
ulating donor T cells at 30, 60, and 105 days after
ransplantation. The mean number of circulating donor
M–derived T cells increased from 400 to 500/L at
ay 30 after transplantation to 900 to 1500/L at day 60
nd 1300 to 1700/L at day 105, without signiﬁcant
ifferences among the BM treatment groups (Figure
A). In contrast, depleting CD11b cells from the BM
raft resulted in a marked and progressive increase of
onor spleen–derived T cells compared with recipients
f unmanipulated BM grafts (Figure 3B). Transplanta-
ion of 0.5 106 spleen cells with CD11b-depleted BM
rafts produced the same effect on increases of spleen-
erived donor T cells as was seen among recipients of
 106 splenocytes, although the absolute number of
pleen-derived T cells in the blood was approximately
alf (data not shown). To exclude an effect by non–T
ells in the splenocyte graft, transplantation of graded
oses of CD11b [] BM cells with 0.3  106 puriﬁed
onor splenic T cells produced the same effect on in-
reases of spleen-derived donor T cells as was seen
mong recipients of unmanipulated splenocytes (Figure
C). Combining data from a variety of different experi-
ents, the increase of spleen-derived T cells was directly
roportional to the content of CD11b cells in the BM
raft (R2
 0.9299) and was inversely proportional to the
ontent of CD11b cells (R2 
 0.1277; Figure 3D).
ecipients of CD11b-Depleted Allogeneic BMT
ad Increased Levels of Serum IFN- at Day 30
fter BMT
To explore potential mechanisms for the observed
ncrease in mature donor-derived CD4 memory T
ells after CD11b depletion of the BM graft, serum
evels of inﬂammatory cytokines were measured at day
30 after transplantation. Day 30 serum levels of
FN- were signiﬁcantly increased in recipients of the
ombination of 5 106 CD11b [] BM and 0.3 106
agnetic activated cell sorting–puriﬁed donor splenic
cells, compared with recipients of unmanipulated
M and CD11b [] BM and the same doses of donor
plenic T cells (P 	 .05; Figure 3E). There was no
igniﬁcant effect of CD11b depletion on day30 se-
um levels of TNF- (data not shown).
emory Spleen-Derived CD4 T Cells Increased
n Mice That Received CD11b-Depleted BM
Examination of the naive (CD62LCD44low) and
emory (CD62LCD44high) subsets of CD4 and
D8 T cells revealed marked increases of spleen-de-
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Immunoregulation by Donor APCs in BMT
Bived CD4 memory T cells in the peripheral blood of
ecipients of donor spleen T cells plus CD11b-depleted
M compared with recipients of unmanipulated BM and
onor splenic T cells (P 	 .01; Table 4). The mean
umber of spleen-derived CD8 memory T cells in the
lood was 28  16/L in recipients of unmanipulated
M, 25  8/L in recipients of CD11b-enriched BM,
nd 22  15/L among recipients of CD11b-depleted
M (P .05). The ratio of CD4 to CD8 donor spleen–
erived memory T cells was signiﬁcantly increased
mong recipients of CD11b [] BM: 12.0  7.1, com-
ared with 5.6  1.5 among recipients of the same dose
f splenic T cells and unmanipulated BM and 2.3  1.2
n recipients of CD11b [] BM (P 	 .05). There were
o signiﬁcant differences in the numbers of spleen- or
igure 2. GVHD clinical scores of recipients of a combination
plenocytes. Clinical signs of GVHD (weight loss, posture, activity,
wice per week up to day 100 according to the procedure described
ach time point were determined in groups of mice that received unm
plenocytes (E), 0.5  106 splenocytes (‚), 1  106 splenocytes (Œ)
epresent the overall mean values  SD for all clinical GVHD score
esults seen in 3 separate experiments. *P 	 .05 comparing the
able 3. GVHD Histopathology Scores of Recipients Transplanted with
plenocytes after Transplantation
BM (5  106) 0 0.5
nmanipulated BM 1.5  0.5 2.5  0.7
D11b [/] BM 1.6  0.5 2.4  0.6
D11b [] BM 1.5  0.6 2.6  0.7
D11b [] BM 1.3  0.5 2.1  0.6
VHD histopathology scores were assessed by means of samples of
than 25% body weight were killed, and the remaining mice wer
in 10% formalin and embedded in parafﬁn: 7-m histology sec
coded. Slides were coded without knowledge of treatment con
criteria [21,28-30]. Gastrointestinal GVHD and hepatic GVHD
inﬁltration of lymphocytes into the periportal regions of the liv
particularly in the crypts, along with foci of epithelial ulceration
score of 0. Severe GVHD with extensive sloughing of intestinal
inﬂammation was given a maximal (sum) score of 8.
D indicates not done; SP, splenocytes.
P 	 .05 compared the GVHD histology scores to those recipients o
splenocytes but different BM grafts.D11b-depleted BM with same dose of splenocytes.
B&MTM-derived naive T cells (data not shown) or the num-
ers of BM-derived CD8 or CD4 memory T cells
mong the recipients that received unmanipulated BM,
D11b [/] BM, CD11b [] BM, or CD11b [] BM
Table 4).
ransplantation with CD11b-Depleted BM and
ow-Dose Donor Splenocytes Conferred
rotection against Posttransplantation Challenge
ith LBRM Tumor Cells
We tested whether the manipulation of the CD11b
ontent of the BM alone, in the absence of added spleno-
ytes, could confer protection against LBRM [20], a
10.BR leukemia cell line, in the C57BL/63B10.BR
ransplant model. Recipients of unmanipulated BM,
anipulated or CD11b-depleted BM and graded doses of donor
ture, and skin integrity; maximum score, 10) were assessed once or
terials and Methods. Mean values for the clinical GVHD score at
ated BM grafts (A) or CD11b-depleted BM grafts (B) plus no added
06 splenocytes (), and 10  106 splenocytes (). The data shown
h of 17 time points for each group and are representative of similar
score between recipients of an unmanipulated BM graft versus
bination of Unmanipulated or Manipulated BM and Graded Doses of
SP Dose (106)
1.0 5.0 10.0
2.8  1.0 4.8  0.9 5.2  0.7
3.4  0.9 5.0  0.6 5.3  0.6
3.4  0.9 5.1  0.6 5.5  0.5
2.5  0.5 3.6  0.9* ND
d gastrointestinal tract from moribund mice; animals that lost more
at day 100. Samples of liver and gastrointestinal tract were ﬁxed
ere stained with hematoxylin and eosin. Five mice per group were
and scored for evidence of GVHD by using previously reported
cored on a scale of 0 to 4. Histologic evidence of GvHD included
apoptotic cells in the intestinal epithelium of the small intestine,
al tissue with no evidence of acute or chronic GVHD was given a
ium and/or apoptosis and extensive hepatic parenchymal injury and
1b[]BM/splenocytes with the recipients of same number of donorof unm
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5D11b [] BM, CD11b [/] BM, or CD11b [] BM
n the absence of low-dose donor lymphocytes died from
rogressive leukemia on day 120 to day 155 after
ransplantation after LBRM challenge on day 75
45-80 days after LBRM infusion; Figure 4A). In con-
igure 3. Expansion of donor-derived T cells after transplantation
ecipient mice were lethally irradiated with 11 Gy on day 2 and u
57BL/6 BM alone () or 1  106 CD45.1CD90.1 C57BL/6 d
M (‚), CD11b [] BM (E), or CD11b [] BM (). Complete bloo
f peripheral blood obtained on day 30, day 60, and day 105
or each condition, and 5 to 10 mice underwent transplantation fo
umber of CD45.1CD90.2 donor BM–derived T cells per micro
pleen graft–derived T cells per microliter of peripheral blood. C, T
fter transplantation was determined in recipients of unmanipulated
uriﬁed donor spleen T cells. D, The correlation between the cont
recursors (●). The mean value of spleen-derived T cells per micro
ifferent numbers of BM cells. E, Mean values  SD of IFN- were
amples of peripheral blood obtained from 5 mice per group of B1
06 unmanipulated or CD11b-depleted C57BL/6 BM plus 0.3 106
he mean values from recipients of CD11b-depleted BM/splenoc
plenocytes.rast, recipients of low-dose splenocytes combined with c
46ompletely or partially CD11b-depleted BM had signif-
cantly better survival compared with recipients of un-
anipulated BM grafts (P 	 .0001 and P 
 .03, respec-
ively) or CD11b [] BM (P 	 .0001 and P 
 .02,
espectively). Recipients of CD11b [] BM and spleno-
nhanced by CD11b depletion of the BM graft. CD45.2 B10.BR
nt transplantation with 5  106 unmanipulated CD45.1CD90.2
plenocytes combined with unmanipulated BM (), CD11b [/]
ts and ﬂow cytometry for T-cell subsets were performed on samples
MT. The transplantation experiment was repeated at least 3 times
condition in each experiment. A, The mean  SD of the absolute
peripheral blood. B, The mean  SD of CD45.1CD90.1 donor
el of donor spleen–derived T cells in peripheral blood on day 60
afts (ﬁlled bar) or CD11b [] BM grafts (open bar) with 0.3  106
CD11b DCs and DC precursors () and CD11b DCs and DC
peripheral blood was determined from multiple experiments with
ined by enzyme-linked immunosorbent assay from day 30 serum
ice lethally irradiated and transplanted with a combination of 5 
-puriﬁed C57BL/6 donor T cells. *P	. 05; ***P	 .001 comparing
fts with the recipients of same number of unmanipulated BM/was e
nderwe
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Beukemia (Figure 4B); moribund mice had clinical or
istopathologic evidence of GVHD (Figure 4C). Mice
hat received unmanipulated BM and donor splenocytes
hat were killed after LBRM challenge had histologic
able 4. The Absolute Number of Donor-Derived CD4 Memory T Ce
Graft
BM 5  106; SP-T 0.3  106)
Donor Sple
Day 30
nmanipulated BM alone 0
nmanipulated BM  SP-T 29  15
D11b [] BM  SP-T 33  11
D11b [] BM  SP-T 66  22†
he absolute number of CD4 memory T cells within the su
posttransplantation blood samples analyzed on days 30 and 
CD4 (of memory spleen-derived or BM-derived) T cells pe
transplantation experiment was repeated at least 3 times for each
experiment.
P 	 .05; †P 	 .01; ‡P 	 .001 comparing the CD4 memory T cell
BM plus splenic T cells.
igure 4. GVL activity of BM and spleen grafts against LBRM in
raft in C57BL/63B10.BR transplants. B10BR recipient mice were
f BM and splenocytes from C57BL/6 donors on day 0. The GVL e
ose of 3  106 LBRM cells on day 75 after transplantation. Th
M (), CD11b [] BM (E), CD11b [/] BM (‚), and CD11b
or 4 experiments. A, Survival of mice transplanted with BM alone
D11b-depleted BM and 1  106 splenocytes with LBRM adm
istopathology of liver from a mouse transplanted with CD11b-dep
fter transplantation, that was killed on day 220 after transplantatio
nmanipulated BM and 1  106 splenocytes, with LBRM adminis
ransplantation.
B&MTndings of leukemia (Figure 4D). A similar survival ben-
ﬁt to CD11b depletion was seen when LBRM was
dministered before allogeneic transplantation (data not
hown).
30 and 60 Days
ived Donor BM Derived
Day 60 Day 30 Day 60
0 312  15 504  19
99  11 282  13 647  22
72  13* 370  10 606  16
392  80‡ 303  14 600  18
of spleen-derived and BM-derived T cells was determined for
escribed in Methods and Materials. The mean value  SD for the
oliter of blood was calculated for each treatment group. The
ion, and 5 to 10 mice were transplanted for each condition in each
ipients of manipulated BM plus splenic T cells with unmanipulated
5 challenge model was enhanced by CD11b depletion of the BM
ly irradiated (11 Gy) on day 2 and received various combinations
the allogeneic transplant was assessed by administration of a lethal
nt of CD11b cells in the BM graft varied among unmanipulated
(). Each treatment group contained 15 or 20 mice pooled from
BRM challenge on day 75. B, Survival of mice transplanted with
ed on day 75 after transplantation. C, Representative GVHD
M and 1  106 splenocytes, with LBRM administered on day 75
epresentative liver histopathology from a mouse transplanted with
n day 75 after transplantation, that was killed on day 120 afterlls at 
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5ransplantation with Partially CD11b-Depleted
M and Low-Dose Donor Splenocytes Conferred
rotection against Pretransplantation Challenge
ith LBRM Tumor Cells
We next tested whether the manipulation of the
D11b content of the BM, in the presence of added
plenocytes, could confer protection against LBRM
ells administered 1 day before BMT. Recipients of
nmanipulated BM alone or the combination of BM
ells with a dose of splenocytes (1  106) that did not
roduce lethal GVHD when transplanted in the ab-
ence of LBBRM (Table 2) died of progressive leuke-B
48ia when 3 106 LBRM cells (10 times the median
ethal dose) were administered 1 day before BMT
Figure 5A). Administration of LBRM to recipients of
nmanipulated BM, CD11b [/] BM, CD11b []
M, or CD11b [] BM without donor splenocytes led
o uniform death from progressive leukemia by day
80 after transplantation (Figure 5B). Conversely, the
ddition of a low dose of donor splenocytes (0.5 106
r 1.0  106) to either CD11b [] BM or CD11b
/] BM conferred signiﬁcant protection against
BRM compared with the same numbers of donor
plenocytes combined with unmanipulated BM (P 

02 and P 
 .0002, respectively) and CD11b [] BM
P 
 .0146 and P 
 .0005, respectively). Of note,
ong-term (200 days) leukemia-free survival was
een in 45% of mice that received 1  106 donor
plenocytes in combination with CD11b [/] BM
rafts (Figure 5C). No long-term survival was seen
mong recipients of CD11b [] BM and 1.0  106
plenocytes that were challenged with LBRM on day
1 because of moderate or severe GVHD pathology
n 6 of 6 evaluable mice. Low amounts of tumor were
een in 2 of 6 mice, and extensive tumor without
VHD was seen in 5 of 5 recipients of LBRM on day
1 that underwent transplantation with unmanipu-
ated BM plus 1  106 splenocytes (comparing the 2
reatment groups, P 
 .02 for the presence of tumor
nd P 
 .001 for the presence of GVHD).
ISCUSSION
This study is the ﬁrst demonstration that the me-
hanical manipulation of a non–T cell and non–stem
ell compartment of an allogeneic BM graft can affect
osttransplantation cellular immune reconstitution.
he expression of CD11b (Mac-1) on DCs and DC
recursors was used as a convenient marker to divide
igure 5. GVL activity of BM and spleen grafts against LBRM in
day 1 challenge model was enhanced by partial CD11b deple-
ion of the BM graft in C57BL/63B10.BR transplants. B10.BR
ecipient mice were lethally irradiated (11 Gy) on day 2 and
eceived various combinations of BM and splenocytes from
57BL/6 donors on day 0. The GVL effect of the allogeneic
ransplant was assessed by administration of a lethal dose of 3 106
BRM cells 1 day before transplantation. The content of CD11b
ells in the BM graft varied among unmanipulated BM (), CD11b
] BM (E), CD11b [/] BM (‚), and CD11b [] BM (). Each
reatment group contained 15 or 20 mice pooled from 3 to 4
xperiments. A, Survival of mice transplanted with LBRM on day
1 with 5  106 BM alone (), 5  106 BM with 1  106
plenocytes (Œ), 5  106 BM with 5  106 splenocytes (●), and 5 
06 BM with 10  106 splenocytes () on day 0. A control group
eceived 1  106 BM with 1  106 splenocytes without LBRM
ﬁlled cross, dashed line). B, Survival of mice transplanted with BM
lone and LBRM on day 1. C, Survival of mice transplanted with
6M grafts and 1  10 splenocytes, and LBRM on day 1.
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Immunoregulation by Donor APCs in BMT
BCs into 2 populations—CD11b DC and CD11b
C subsets—and to selectively deplete a portion of
C precursors without signiﬁcantly altering the con-
ent of donor T cells or donor multipotent HPCs in
he graft (Table 1). Because we used different con-
enic strains as BM donors and donors of mature
splenic) T cells, these results demonstrate a trans-
ffect of regulatory BM cells on donor T-cell activa-
ion and expansion that is not explained by alterations
n the content of donor T cells or T-cell precursors,
ncluding pluripotent or committed lymphoid progen-
tors [33,34]. Manipulation of the content of CD11b
ells in the BM graft alone did not lead to survival
ifferences after allogeneic BMT with the C57BL/
3B10.BR transplant model system, nor did it affect
ngraftment rates (97% in all treatment groups that
eceived 5  106 BM cells). Of note, there was no
nhanced GVL effect after CD11b depletion of the
M graft in the absence of donor T cells in the
plenocyte graft (Figure 4A). However, CD11b deple-
ion of the BM graft synergized with co-transplanta-
ion of low-dose splenocytes to produce a signiﬁcant
xpansion of donor CD4 memory T cells with in-
reased GVL activity and higher levels of serum
FN- 1 month after transplantation (Figure 3B
nd E).
We evaluated the clinical relevance of the ob-
erved effect on enhanced posttransplantation im-
une reconstitution in a B10.BR tumor model that is
menable to immunotherapy. The recipients of BM
nd CD11b-enriched BM grafts in combination with
ow doses of donor splenocytes had 90% to 100%
urvival (Table 2) with no signiﬁcant evidence of clin-
cal GVHD (Figure 2) and no measurable excess
VHD pathology compared with recipients of BM
lone (Table 3). In contrast, recipients of CD11b
/] BM or CD11b [] BM in combination with
ow-dose donor splenocytes had signs of mild clinical
VHD (transient weight loss; Figure 2) and slightly
ncreased GVHD pathology scores compared with
ontrols of BM alone (Table 3). The enhanced im-
une reconstitution observed among recipients of
D11b-depleted BM and low-dose donor splenocytes
as associated with enhanced GVL activity and sig-
iﬁcantly improved long-term survival after leukemia
hallenge (Figure 4B). In our pretransplantation (day
1) LBRM challenge model, recipients of partially
D11b-depleted BM and low-dose donor splenocytes
ad enhanced GVL activity and signiﬁcantly im-
roved long-term survival after leukemia challenge
Figure 5C). In contrast, there were no long-term
urvivors among recipients of CD11b-depleted BM,
ow-dose donor splenocytes, and LBRM (Figure 5C)
ecause of increased mortality from GVHD (data not
hown).
Our data support the hypothesis that the effect of
D11b depletion of the BM graft is to enhance the
B&MTeffectiveness of alloantigen presentation. Thus, trans-
plantation of the combination of IL-2–producing
LBRM tumor cells and CD11b-depleted BM on day
1 led to enhanced GVL and GVHD effects, leading
to eradication of tumor at the expense of increased
fatal GVHD due either to direct alloantigen presen-
tation by the host-type LBRM tumor cells, as de-
scribed by Shlomchik et al. [2], or to enhanced alloan-
tigen presentation by CD11b-depleted BM in the
context of IL-2 secreted by tumor cells. In contrast,
transplantation of a CD11b-depleted graft and low-
dose splenocytes in the absence of tumor cells at day 0
led to an increase in alloreactivity in donor T cells that
was manifested predominantly as increased numbers
of donor-derived T-cells in posttransplantation blood
samples and increased levels of serum IFN-. The net
result of complete CD11b depletion of the marrow
graft was an enhanced GVL effect, as assessed by
resistance to a lethal dose of tumor cells administered
on day 75.
Overall, the GVL effect in the B10.BR recipients
of C57BL/6 BM and spleen cell grafts was parallel to
the degree of donor splenic T-cell increases after
transplantation (Figure 3B and C). The predominant
phenotype of the donor spleen–derived T cells was
memory CD4 T cells: CD4CD62LCD44high.
These data suggest that mature memory T cells de-
rived from spleen cell inocula rather than de novo
donor T cells generated during thymopoiesis from
BM HPCs mediated the major GVL effect. These
data further suggest that improved GVL activity of
donor splenic T cells is associated with memory
CD4 T-cell [22] activation by the remaining
CD11b donor APCs or the release of donor T cells
from the immune suppression mediated by donor BM
CD11b cell populations. Although activation or al-
loactivation of naive donor CD4 spleen-derived T
cells could be followed by their transition into the
memory T-cell pool [35], we have previously shown
that donor memory (and not naive) CD4 T cells
mediate a GVL effect against LBRM in the C57BL/
63B10.BR transplant model [36].
These data support the hypothesis that CD11b
depletion either removes a regulatory BM population
that inhibits alloactivation and expansion of donor T
cells or enriches a regulatory BM population that
enhances alloactivation and expansion of donor T
cells. It is possible that relative enrichment of BM
CD3 T cells in the CD11b-depleted BM allograft
could affect posttransplantation donor T-cell expan-
sion, but the speciﬁc effect of CD11b depletion on the
expansion of mature T cells present in the spleen graft
(and not on BM T cells) makes this unlikely. Alterna-
tive hypotheses notwithstanding, the observed effects
on enhanced expansion of CD4memory T cells with
GVL activity is consistent with a model of indirect
antigen presentation by donor DCs to naive donor
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5D4 T cells. These results are consistent with the
odel that donor CD11b DCs inhibit the genera-
ion of donor memory T cells with donor antihost
ytopathic activity [37,38] or that increased numbers
f donor CD11b DCs enhance donor T-cell activa-
ion and proliferation.
In conclusion, the data presented herein support
he hypothesis that donor APCs in the BM allograft
ave a signiﬁcant immunoregulatory effect on post-
ransplantation cellular immune reconstitution and
hat manipulation of the content of donor APCs in the
M allograft may translate into enhanced GVL activ-
ty without signiﬁcant GVHD.
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